COVID-19: an unexpected indication for anti-rheumatic therapies?
作者信息
Lucchino Bruno, Di Franco Manuela, Conti Fabrizio
机构信息
Rheumatology Unit, Department of Internal Clinical, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
出版信息
Rheumatology (Oxford). 2020 Jun 1;59(6):1200-1203. doi: 10.1093/rheumatology/keaa194.
Abstract
摘要
相似文献
1
COVID-19: an unexpected indication for anti-rheumatic therapies?
Rheumatology (Oxford). 2020 Jun 1;59(6):1200-1203. doi: 10.1093/rheumatology/keaa194.
2
What is the role of rheumatologists in the era of COVID-19?
Autoimmun Rev. 2020 Jun;19(6):102539. doi: 10.1016/j.autrev.2020.102539. Epub 2020 Apr 3.
3
Thoughts on COVID-19 and autoimmune diseases.
Lupus Sci Med. 2020 Apr 3;7(1):e000396. doi: 10.1136/lupus-2020-000396. eCollection 2020.
4
Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab.
Infection. 2020 Oct;48(5):767-771. doi: 10.1007/s15010-020-01476-7. Epub 2020 Jul 8.
5
COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking.
Virus Res. 2020 Sep;286:198070. doi: 10.1016/j.virusres.2020.198070. Epub 2020 Jun 20.
6
Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.
J Autoimmun. 2020 May;109:102442. doi: 10.1016/j.jaut.2020.102442. Epub 2020 Apr 2.
7
Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials.
Eur Urol Focus. 2020 Sep 15;6(5):1028-1031. doi: 10.1016/j.euf.2020.05.019. Epub 2020 Jun 5.
8
Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Int Immunopharmacol. 2020 Sep;86:106749. doi: 10.1016/j.intimp.2020.106749. Epub 2020 Jul 1.
9
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.
Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4. Epub 2020 Feb 4.
10
Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know.
Ann Intern Med. 2020 Jun 2;172(11):754-755. doi: 10.7326/M20-1334. Epub 2020 Mar 31.
引用本文的文献
1
SARS-CoV-2-induced venous thromboembolism in a patient with VEXAS syndrome.
Rheumatol Adv Pract. 2023 Jan 20;7(1):rkad012. doi: 10.1093/rap/rkad012. eCollection 2023.
2
Clinical Features and Outcomes of Coronavirus Disease 2019 in Patients with Inflammatory Bowel Disease and Spondyloarthropathies.
Turk J Gastroenterol. 2022 Sep;33(9):751-759. doi: 10.5152/tjg.2022.22181.
3
An insight into SARS-CoV-2 structure, pathogenesis, target hunting for drug development and vaccine initiatives.
RSC Med Chem. 2022 Jan 25;13(6):647-675. doi: 10.1039/d2md00009a. eCollection 2022 Jun 22.
4
Licorice () Extracts-Suitable Pharmacological Interventions for COVID-19? A Review.
Plants (Basel). 2021 Nov 26;10(12):2600. doi: 10.3390/plants10122600.
5
Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.
Rheumatology (Oxford). 2021 Jan 5;60(1):399-407. doi: 10.1093/rheumatology/keaa587.
6
Does immunosuppressive treatment entail an additional risk for children with rheumatic diseases? A survey-based study in the era of COVID-19.
Rheumatol Int. 2020 Oct;40(10):1613-1623. doi: 10.1007/s00296-020-04663-9. Epub 2020 Aug 2.
7
Why not to use colchicine in COVID-19? An oldanti-inflammatory drug for a novel auto-inflammatory disease.
Rheumatology (Oxford). 2020 Jul 1;59(7):1769-1770. doi: 10.1093/rheumatology/keaa217.
8
[Not Available].
Rev Rhum Ed Fr. 2020 May;87(3):150-152. doi: 10.1016/j.rhum.2020.03.010. Epub 2020 Apr 24.
9
Old and new antirheumatic drugs for the treatment of COVID-19.
Joint Bone Spine. 2020 May;87(3):195-197. doi: 10.1016/j.jbspin.2020.03.013.
本文引用的文献
1
Increasing host cellular receptor-angiotensin-converting enzyme 2 expression by coronavirus may facilitate 2019-nCoV (or SARS-CoV-2) infection.
J Med Virol. 2020 Nov;92(11):2693-2701. doi: 10.1002/jmv.26139. Epub 2020 Jul 2.
2
Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19).
Front Immunol. 2020 May 1;11:827. doi: 10.3389/fimmu.2020.00827. eCollection 2020.
3
Effective treatment of severe COVID-19 patients with tocilizumab.
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.
4
Molecular immune pathogenesis and diagnosis of COVID-19.
J Pharm Anal. 2020 Apr;10(2):102-108. doi: 10.1016/j.jpha.2020.03.001. Epub 2020 Mar 5.
5
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
6
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
7
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
8
Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools.
Virol Sin. 2020 Jun;35(3):266-271. doi: 10.1007/s12250-020-00207-4. Epub 2020 Mar 3.
9
COVID-19: combining antiviral and anti-inflammatory treatments.
Lancet Infect Dis. 2020 Apr;20(4):400-402. doi: 10.1016/S1473-3099(20)30132-8. Epub 2020 Feb 27.
10
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.
JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.
Zotero 插件